Innate Pharma
Nasdaq IPHA · Marseille, France
Works in Dermatology · GI & liver · Hematology · Immunology · Metabolic & endocrine · Oncology · Renal & urogenital · Respiratory · Women's health
Innate Pharma is a clinical trial sponsor based in Marseille, France, listed as Nasdaq IPHA. It has 2 active clinical trials with 215 planned participants, across 9 therapeutic areas. Since 2021 it has completed 5 trials and stopped 2 early.
Trial track record · since 2021
Financials · Nasdaq IPHA
Pipeline · 2 active trials
| Stage | Trial | Status |
|---|---|---|
On the market
1 approved drug application with a product on the market.
Questions about Innate Pharma
Innate Pharma is lead sponsor of 2 active clinical trials on ClinicalTrials.gov, with 215 planned participants, in Dermatology, GI & liver, Hematology, Immunology and other areas. Since 2021 it has completed 5 trials and stopped 2 early.
Innate Pharma is based in Marseille, France and is listed as Nasdaq IPHA. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Innate Pharma; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-07-27.
Approve Suite is not affiliated with Innate Pharma.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.